ciclosporin
use
mani
year
treatment
felin
hypersensit
dermat
variou
dose
gener
rang
dose
mgkg
given
daili
recent
test
random
blind
parallel
group
studi
shown
efficaci
well
cat
head
neck
excori
alopecia
eosinophil
plaqu
andor
miliari
dermat
administr
mgkg
ciclosporin
daili
week
result
decreas
total
lesion
pruritu
sever
score
cat
receiv
mgkg
daili
dose
common
advers
event
mild
gastrointestin
disord
studi
aim
establish
efficaci
safe
dose
dose
durat
limit
week
address
use
ciclosporin
treat
felin
hypersensit
dermat
cat
limit
inform
avail
efficaci
safeti
ciclosporin
studi
suggest
felin
hypersensit
dermat
well
control
dose
taper
howev
frequenc
respons
dose
taper
document
cat
present
studi
design
assess
clinic
respons
regimen
toler
ciclosporin
administ
week
studi
conduct
two
phase
first
phase
establish
mgkg
effect
dose
ciclosporin
treatment
hypersensit
present
studi
present
outcom
second
phase
regimen
examin
briefli
phase
studi
blind
random
parallel
group
studi
ciclosporin
dose
oral
mgkg
administ
daili
week
compar
placebo
control
treatment
hypersensit
dermat
clinic
respons
assess
week
start
treatment
phase
studi
explor
effect
regimen
clinic
respons
ciclosporin
studi
immedi
follow
phase
studi
random
blind
clinic
observ
made
investig
inclus
visit
day
phase
day
final
visit
phase
week
day
day
day
phase
studi
multicentr
site
locat
usa
franc
uk
belgium
switzerland
conduct
accord
procedur
principl
good
clinic
practic
cat
owner
sign
inform
consent
cat
includ
free
withdraw
anim
point
cat
includ
phase
diagnosi
hypersensit
dermat
made
rule
flea
bite
hypersensit
bacteri
fungal
infect
food
allergi
also
evalu
case
exclus
whenev
possibl
cat
evalu
felin
leukaemia
viru
felin
immunodefici
viru
infect
exclud
found
posit
toxoplasma
serolog
statu
assess
prior
inclus
usa
cat
toxoplasma
posit
serolog
titr
exclud
eu
site
exclus
made
base
toxoplasma
serolog
titr
cat
complet
phase
except
exhibit
advers
event
result
studi
withdraw
poor
owner
complianc
elig
particip
phase
includ
studi
cat
minimum
month
age
kg
bodi
weight
exclus
criteria
includ
follow
breed
pregnant
lactat
cat
presenc
activ
system
infect
evid
histori
type
malign
uncontrol
ectoparasit
infest
requir
vaccin
studi
feed
uncook
diet
assess
determin
clinic
effect
dose
taper
made
compar
initi
investig
examin
baselin
phase
overal
clinic
improv
visit
visit
clinic
improv
assess
follow
excel
clinic
sign
observ
first
examin
complet
disappear
good
clear
amelior
clinic
sign
compar
initi
examin
accept
clinic
improv
compar
initi
examin
cat
respond
slightli
treatment
poor
clinic
statu
cat
compar
initi
examin
chang
bad
clinic
statu
cat
compar
initi
examin
deterior
investig
evalu
sever
lesion
pruritu
everi
visit
lesion
sever
measur
use
scorfad
score
felin
allerg
dermat
score
system
previous
partli
scorfad
numer
rate
score
system
assess
sever
excori
ex
alopecia
sa
miliari
dermat
md
eosinophil
granuloma
eo
bodi
area
result
total
lesion
score
tl
visual
analog
scale
use
determin
owner
pruritu
score
op
base
owner
observ
cat
behaviour
previou
day
line
mark
one
end
scale
indic
cat
comfort
normal
groom
behaviour
end
show
cat
uncomfort
groom
time
addit
numer
rate
scale
use
determin
investig
pruritu
score
ip
previous
overal
assess
clinic
respons
made
investig
owner
visit
phase
studi
assess
score
like
phase
visit
begin
day
studi
exit
day
phase
cat
complet
studi
ciclosporin
provid
novarti
anim
health
basel
switzerland
mgml
liquid
formul
contain
glass
bottl
dosag
ciclosporin
deliv
either
via
minipump
devic
attach
bottl
activ
manual
use
syring
calibr
deliv
requir
volum
treatment
accuraci
ciclosporin
administ
cat
either
cat
food
directli
cat
mouth
owner
instruct
withdraw
cat
food
suffici
period
time
possibl
encourag
cat
eat
medic
food
cat
refus
treatment
two
consecut
dose
attempt
offer
food
owner
instruct
administ
treatment
directli
cat
mouth
immedi
feed
inclus
studi
day
day
cat
administ
daili
oral
dose
mgkg
ciclosporin
independ
previou
treatment
receiv
phase
day
dose
taper
determin
accord
investig
overal
assess
clinic
respons
comparison
first
day
inclus
phase
studi
anim
receiv
ciclosporin
target
dose
mgkg
frequenc
dose
could
alter
everi
day
eod
twice
weekli
tw
present
tabl
investig
could
adjust
dose
visit
back
previou
dose
regimen
time
deem
necessari
anim
return
previou
dose
regimen
visit
anim
evalu
next
schedul
visit
dose
regimen
maintain
adjust
accord
clinic
respons
describ
treatment
accept
evalu
owner
dose
administr
throughout
durat
phase
studi
cat
receiv
flea
adulticid
treatment
regular
interv
accord
manufactur
recommend
except
one
site
locat
geograph
area
consid
flea
free
medic
intervent
like
signific
effect
efficaci
paramet
topic
system
glucocorticosteroid
includ
ophthalm
prepar
megestrol
acet
antihistamin
clomipramin
amitriptylin
fluoxetin
topic
calcineurin
inhibitor
immunotherapi
prohibit
studi
essenti
fatti
acid
shampoo
author
use
studi
initi
maintain
throughout
studi
drug
interf
ciclosporin
ketoconazol
itraconazol
erythromycin
phenobarbit
also
prohibit
given
continu
day
vaccin
given
prior
studi
start
phase
concomit
medic
treatment
gastrointestin
parasiticid
medic
therapeut
effect
unrel
treat
dermatolog
diseas
allow
long
strictli
document
case
sever
facialneck
pruritu
discret
investig
elizabethan
collar
could
use
begin
studi
maximum
day
thereaft
cat
remain
owner
usual
home
durat
studi
owner
instruct
chang
home
manag
diet
cat
studi
allow
cat
fed
separ
anim
household
ensur
nonstudi
anim
ingest
test
materi
administ
food
owner
encourag
restrict
cat
hunt
scaveng
offer
commerci
cook
diet
durat
studi
addit
full
physic
examin
bodi
weight
determin
visit
blood
sampl
collect
haematolog
biochemistri
inclus
studi
end
case
prematur
withdraw
advers
event
ae
monitor
owner
investig
throughout
studi
ae
consid
observ
unfavour
unintend
occur
administr
ciclosporin
whether
consid
relat
treatment
seriou
ae
defin
advers
reaction
result
death
life
threaten
result
signific
disabl
incapac
result
perman
prolong
sign
signific
ae
includ
requir
activ
medic
intervent
consid
investig
clinic
signific
ae
regardless
causal
record
studi
dose
taper
measur
cat
popul
present
full
period
separ
two
visit
phase
summari
statist
mean
profil
plot
miss
valu
imput
use
last
observ
carri
forward
method
order
obtain
approxim
compar
data
anim
miss
valu
bodi
weight
compar
studi
use
student
pair
within
subgroup
influenc
vomit
bodi
weight
assess
ancova
model
includ
subgroup
time
subgroup
time
interact
age
baselin
weight
vomit
haematolog
clinic
chemistri
paramet
compar
subgroup
ancova
model
includ
subgroup
baselin
valu
statist
calcul
perform
use
softwar
version
particular
use
proc
univari
proc
mix
sa
institut
cari
nc
usa
cat
particip
phase
studi
elig
inclus
phase
cat
complet
phase
studi
withdrew
studi
shown
figur
cat
popul
consist
male
femal
cat
age
year
time
enrol
mean
age
year
mean
bodi
weight
kg
rang
kg
thirteen
breed
repres
approxim
studi
anim
domest
short
hair
european
short
hair
per
cent
cat
receiv
commerci
food
live
indoor
live
indoor
outdoor
one
cat
live
outdoor
ciclosporin
administ
directli
mouth
cat
taken
mix
food
case
seven
case
mix
method
use
inform
miss
dose
could
taper
shown
tabl
cat
receiv
daili
dose
mgkg
ciclosporin
day
phase
dose
administ
eod
cat
remain
studi
repres
total
cat
popul
includ
studi
interv
dose
administr
could
extend
tw
cat
still
studi
day
repres
initi
cat
popul
cat
still
studi
initi
popul
remain
daili
treatment
studi
end
addit
regimen
similar
regardless
observ
lesion
type
inclus
phase
studi
consid
cat
still
studi
week
phase
frequenc
eod
treatment
cat
lesion
eo
ex
md
sa
respect
week
ciclosporin
administ
tw
cat
present
eo
ex
md
sa
lesion
figur
show
inclus
phase
week
phase
mean
tl
decreas
improv
phase
baselin
week
phase
tl
score
remain
essenti
stabl
mean
final
tl
improv
p
phase
baselin
respons
similar
independ
treatment
receiv
phase
pruritu
sever
improv
similar
manner
tl
shown
figur
illustr
owner
assess
visual
analog
scale
phase
mean
baselin
score
decreas
week
phase
remain
stabl
studi
end
final
visit
mean
op
overal
mean
op
score
improv
p
week
respect
addit
cat
consid
groom
time
often
agit
nervou
enrol
phase
still
behav
way
phase
studi
end
proport
cat
groom
normal
groom
calm
improv
eight
enrol
phase
phase
studi
end
overal
studi
exit
lesion
mild
lesion
tl
cat
frequenc
complet
resolut
lesion
differ
depend
type
lesion
initi
observ
inclus
phase
complet
resolut
eo
ex
md
sa
lesion
cat
present
respect
lesion
inclus
phase
studi
end
investig
assess
overal
efficaci
excel
good
accept
poor
bad
similar
assess
made
owner
data
shown
ciclosporin
use
conjunct
variou
medic
includ
macrocyl
lacton
antiparasit
agent
nutrit
supplement
topic
skin
otic
cleanser
antimicrobi
cat
treat
ciclosporin
concurr
system
antimicrobi
cat
treat
ciclosporin
receiv
macrocyl
lacton
advers
event
report
cat
phase
studi
tabl
present
ae
cat
frequenc
use
system
organ
classif
digest
tract
disord
frequent
report
ae
includ
primarili
vomit
cat
report
ae
diarrhoea
cat
report
ae
also
report
anorexia
lethargi
sneez
weight
loss
eighti
per
cent
report
ae
occur
cat
receiv
daili
dose
ciclosporin
two
cat
posit
toxoplasma
gondii
seroconvers
studi
one
case
toxoplasma
titr
request
studi
end
cat
letharg
elev
creatinin
phosphokinas
cat
remain
clinic
normal
igg
igm
neg
case
toxoplasma
titr
measur
cours
phase
studi
cat
letharg
igg
neg
igm
case
sign
lethargi
andor
elev
valu
creatinin
phosphokinas
note
one
cat
studi
note
anorexia
elev
liver
enzym
alanin
aminotransferas
alkalin
phosphatas
valu
alanin
aminotransferas
improv
baselin
prior
phase
iul
exit
phase
iul
alkalin
phosphatas
valu
remain
elev
prestudi
baselin
iul
studi
exit
phase
iul
cat
withdrawn
recov
cat
show
trend
slight
temporari
weight
loss
initi
daili
dose
mgkg
shown
figur
phase
phase
bodi
weight
anim
receiv
dose
regimen
daili
dose
show
signific
overal
weight
loss
p
addit
correl
bodi
weight
chang
frequenc
vomit
p
clinic
chemistri
haematolog
valu
evalu
prior
ciclosporin
administr
studi
end
signific
differ
note
haematolog
mean
alanin
aminotransferas
alkalin
phosphatas
albumin
significantli
lower
anim
treat
daili
ciclosporin
comparison
anim
dose
regimen
howev
mean
paramet
valu
remain
within
normal
refer
rang
cat
alanin
aminotransferas
iul
alkalin
phosphatas
iul
albumin
gl
total
six
cat
withdrawn
per
studi
protocol
due
develop
ae
clinic
sign
includ
diarrhoea
depress
lethargi
anorexia
vomit
one
case
subsequ
diagnos
felin
infecti
periton
euthan
one
diagnos
gondii
infect
anoth
one
diagnos
hyperthyroid
cat
diagnos
hyperthyroid
withdrawn
studi
owner
owner
elect
treat
cat
die
appar
uncontrol
hyperthyroid
studi
exit
anim
except
felin
infecti
periton
hyperthyroid
case
recov
remain
clinic
normal
follow
daili
administr
mgkg
minim
durat
week
dose
ciclosporin
could
taper
eod
cat
remain
studi
possibl
taper
dose
tw
cat
complet
studi
similar
frequenc
dose
taper
previous
report
cat
suffer
idiopath
pruritu
eosinophil
plaqu
indol
ulcer
andor
linear
vercelli
et
show
follow
week
cat
receiv
induc
dose
ciclosporin
dose
could
administ
tw
cat
eod
cat
overal
would
appear
frequenc
dose
taper
overestim
base
cat
popul
remain
studi
underestim
base
initi
popul
includ
studi
clinic
studi
frequenc
treatment
interrupt
may
higher
gener
practic
condit
cat
belong
owner
compli
protocol
withdrawn
furthermor
note
frequenc
dose
taper
observ
clinic
studi
may
predict
precis
observ
clinic
practic
clinic
trial
strict
standard
rule
given
taper
dose
clinic
practic
dose
adjust
may
base
variou
consider
includ
limit
clinic
improv
addit
clinic
trial
ciclosporin
gener
use
monotherapi
use
concomit
medic
restrict
much
possibl
cat
treat
clinic
practic
may
receiv
adjunct
therapi
may
contribut
clinic
improv
also
like
owner
complianc
treatment
better
clinic
trial
compar
clinic
practic
owner
complianc
regularli
monitor
drug
account
assess
factor
may
contribut
respons
ciclosporin
treatment
therefor
affect
frequenc
dose
taper
howev
larg
proport
cat
studi
dose
could
taper
eod
even
tw
without
deterior
clinic
respons
addit
per
protocol
analysi
carri
assess
influenc
prohibit
concurr
medic
noncompli
treatment
administr
treatment
regimen
outcom
cat
wear
elizabethan
collar
longer
author
day
receiv
system
concomit
therapi
antibiot
treatment
bacteri
dermat
cat
antihistamin
one
cat
might
contribut
clinic
improv
lesion
complet
partli
exclud
per
protocol
analysi
analysi
reveal
mark
differ
compar
analysi
dose
taper
clinic
paramet
total
lesion
score
pruritu
data
shown
indic
limit
influenc
complianc
concomit
therapi
clinic
outcom
frequenc
extent
dose
taper
appear
much
higher
cat
dog
systemat
review
clinic
studi
frequenc
eod
treatment
follow
week
induct
period
found
gener
close
rule
dog
could
dose
twice
week
mainten
differ
algorithm
use
clinic
studi
decid
chang
dose
dog
cat
dog
chang
dose
frequenc
guid
rel
improv
canin
atop
dermat
extent
sever
lesion
score
baselin
cat
chang
dose
regimen
base
overal
clinic
assess
made
investig
dose
could
taper
good
excel
respons
obtain
correspond
approxim
improv
lesion
score
threshold
select
dog
studi
chang
dose
could
expect
frequenc
dose
reduct
would
lower
cat
dog
cat
dose
could
taper
moder
sever
pruritu
still
exhibit
whilst
dog
reduct
lesion
score
suffici
dose
taper
even
persist
pruritu
pharmacokinet
featur
ciclosporin
dog
cat
may
explain
differ
frequenc
cat
blood
concentr
dose
ciclosporin
tend
compar
higher
howev
concentr
ciclosporin
need
inhibit
express
immunomodulatori
cytokin
peripher
blood
mononuclear
cell
appear
higher
cat
inform
precis
mode
action
ciclosporin
skin
crucial
target
cell
would
need
interpret
differ
regimen
initi
similar
four
type
lesion
observ
complet
resolut
lesion
less
frequent
cat
suffer
alopecia
type
lesion
slow
hair
regrowth
gener
seen
winter
follicl
activ
unlik
explain
incomplet
resolut
induc
alopecia
studi
conduct
differ
geograph
area
climat
condit
sever
season
possibl
excess
groom
associ
behaviour
may
contribut
perpetu
alopecia
sever
prolong
pruritu
induc
state
anxieti
behaviour
form
viciou
cycl
studi
may
includ
cat
psychogen
alopecia
definit
diagnosi
psychogen
alopecia
difficult
anxiou
condit
may
resolv
spite
improv
pruritu
interestingli
durat
induct
period
start
dose
mgkg
daili
influenc
clinic
respons
week
total
lesion
score
pruritu
sever
similar
whether
cat
receiv
ciclosporin
week
mgkg
cat
phase
placebo
group
week
cat
enrol
receiv
high
dose
phase
indic
extend
durat
treatment
induc
dose
mgkg
daili
like
result
better
clinic
respons
also
noteworthi
clinic
respons
remain
stabl
dose
taper
independ
previou
treatment
receiv
phase
studi
show
chang
dose
regimen
result
stabl
respons
dose
adjust
compens
deterior
diseas
rare
need
return
previou
dose
regimen
studi
visit
requir
cat
phase
treatment
complianc
good
three
cat
withdrawn
studi
cat
would
accept
medic
either
food
dose
directli
mouth
cat
took
formul
mix
food
major
studi
durat
volum
formul
mix
food
small
mlkg
potenti
tast
product
could
mask
mix
palat
food
studi
report
ae
occur
daili
ciclosporin
administr
observ
ae
consist
alreadi
report
cat
receiv
gastrointestin
ae
frequent
report
vomit
event
seen
approxim
case
vomit
tend
resolv
without
discontinu
treatment
possibl
vomit
event
relat
ciclosporin
vomit
also
observ
cat
enrol
previou
like
vomit
diarrhoea
gener
mild
requir
medic
intervent
weight
loss
note
cat
treat
daili
mgkg
ciclosporin
phase
studi
control
cat
previous
expos
phase
administ
ciclosporin
phase
studi
correl
found
weight
loss
frequenc
vomit
event
weight
loss
probabl
result
combin
gastrointestin
disturb
effect
food
intak
element
reduc
decreas
dose
frequenc
major
cat
weight
loss
treat
ciclosporin
tend
regain
weight
result
overal
weight
loss
studi
end
cat
diagnos
seriou
ae
felin
infecti
periton
probabl
previous
undiagnos
condit
toxoplasmosi
associ
ciclosporin
monotherapi
anecdot
cat
seroneg
gondii
may
risk
develop
clinic
toxoplasmosi
becom
infect
undergo
treatment
ciclosporin
potenti
exposur
seroneg
cat
cat
suspect
seroneg
gondii
therefor
minim
eg
keep
indoor
avoid
feed
raw
meat
scaveng
possibl
exacerb
seriou
system
diseas
eg
felin
infecti
periton
consist
known
pharmacolog
class
drug
case
clinic
toxoplasmosi
seriou
system
ill
treatment
ciclosporin
withdrawn
appropri
therapi
initi
ciclosporin
inhibitor
transport
coadministr
ciclosporin
substrat
macrocycl
lacton
could
therefor
potenti
decreas
efflux
drug
barrier
cell
potenti
result
sign
central
nervou
system
toxic
studi
cat
requir
treat
flea
adulticid
rule
flea
allergi
caus
allerg
diseas
cat
subsequ
treat
ciclosporin
receiv
concomit
treatment
macrocycl
lacton
treat
selamectin
one
cat
receiv
milbemycin
praziquantel
approxim
cat
experienc
ae
primarili
digest
tract
disord
one
cat
treat
selamectin
report
convuls
convuls
attribut
possibl
chronic
renal
diseas
cat
continu
ciclosporin
studi
report
number
anim
ciclosporin
macrocycl
lacton
therapi
limit
extrapol
made
caution
appear
associ
concomit
use
drug
report
neurolog
ae
conclus
result
suggest
induc
dose
mgkg
ciclosporin
taper
soon
week
without
deterior
clinic
respons
dose
regimen
could
taper
eod
tw
greater
cat
enter
studi
although
ciclosporin
treatment
appear
gener
well
toler
data
also
suggest
establish
lowest
effect
dose
regimen
ciclosporin
treatment
improv
safeti
profil
drug
author
would
like
thank
studi
investig
contribut
case
luc
beco
andrea
cannon
paul
coward
chri
dale
claud
favrot
eric
florant
jacqu
fontain
peter
forsyth
cecilia
friberg
thierri
hazan
juli
henfrey
john
hutt
jamet
janet
littlewood
linda
messing
neil
mcewan
donald
mactaggart
tim
nuttal
pascal
tiffani
tapp
randal
thoma
patricia
white
author
would
also
like
thank
cat
owner
atopica
cat
team
novarti
anim
health
